I'm LongbridgeAI, I can summarize articles.Zura Bio's target price soars 350% above current levels as Guggenheim maintains Buy rating; XCUR races against Nasdaq's December 2 delisting deadline; SRx Health pursues strategic acquisitions while East West Bancorp reports 3.48% sequential revenue growth.
Zura Bio (ZURA.US) is making waves with Guggenheim's bullish stance, projecting a target price 351.56% above recent trading levels amid its clinical-stage pipeline for alopecia treatment. Meanwhile, Exicure (XCUR.US) races against Nasdaq's December 2 deadline to restore shareholder equity compliance after receiving delisting warnings in September. SRx Health Solutions (SRXH.US) has quietly built momentum through strategic moves including a Vistagen Therapeutics stake acquisition and CERo financing deal. East West Bancorp (EWBC.US) stands out with Q3 revenue growth of 3.48% and stable net interest margins at 3.93%. UroGen Pharma (URG.US) advanced its urology oncology focus through a Jazz Pharmaceuticals collaboration, while Dun & Bradstreet (DNB.US) reported steady data services expansion. Manitowoc (MANE.US) unveiled new crane models targeting infrastructure demand, Bitcoin ETF (SBIT.US) crossed $1 billion in assets under management, and Mission Broadcasting (MSS.US) completed its Nexstar acquisition. Data Storage Corporation (DTST.US) strengthened enterprise positioning via IBM cloud storage partnerships.